Neuroscience 2001 Abstract
| Presentation Number: | 842.16 |
|---|---|
| Abstract Title: | Preliminary results of cannabis extract for refractory urinary tract dysfunction in advanced multiple sclerosis. |
| Authors: |
Brady, C. M.*1
; Berkley, K. J.1,2
; Wiseman, O. J.1
; Haslam, C.1
; Fowler, C. J.1
1Dept Uro-Neurol, Nat Hosp Neurol Neurosurg, London, United Kingdom 2Prog Neurosci, Fl St Univ, Tallahassee, FL |
| Primary Theme and Topics |
Autonomic, Limbic and Other Systems - Autonomic -- Gastrointestinal and urogenital regulation |
| Secondary Theme and Topics | Neurological and Psychiatric Conditions<br />- Demyelinating Disorders |
| Session: |
842. Autonomic: gastrointestinal and urogenital regulation IV Poster |
| Presentation Time: | Wednesday, November 14, 2001 4:00 PM-5:00 PM |
| Location: | Exhibit Hall QQ-4 |
| Keywords: | cannabinoid, bladder, micturition, spasticity |
Indwelling bladder catheters are the only therapeutic option for some patients with advanced multiple sclerosis and troublesome bladder symptoms. Favourable patient reports together with animal studies demonstrating cannabinoid receptors in the bladder and brain regions associated with bladder control encouraged clinical investigation of cannabinoids as a possible therapeutic option. When cannabis-based medical extract (CBME) became available for clinical trials in the UK, this open-label pilot study was initiated. Here we report results from the first 7 patients (1M:6F, age range 31-51) who followed an 8-wk course of patient-controlled doses of sublingual sprays of CBME (each spray: 2.5mg each of delta-9-tetrahydrocannibinol and cannabidiol). Assessment included home diary reports of urinary and other symptoms, and bladder cystometry before and after maximum tolerated dose of CBME. By 8 weeks, all patients showed improvement in some urinary symptoms. Daily incontinence episodes decreased on average by 50%. Daytime urinary frequency decreased from 10 to 8 per day (p=0.03). Although bladder capacity without CBME use for the previous 24h increased from a baseline of 302ml to 345ml (p=0.37), suggesting no long-term effect, it increased to 438ml after administration of CBME (p=0.04), showing an acute effect. These preliminary pilot results indicate that CBME may prove to be an effective additional treatment for ameliorating some urinary symptoms in some patients with advanced multiple sclerosis.
Supported by The Medical Cannabis Research Foundation (CJF) and NIH grant RO1 NS11892 (KJB).
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2001 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2001. Online.
Copyright © 2001-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
